BiotechTube

Osilodrostat

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cushing's Syndrome

Conditions

Cushing's Syndrome

Trial Timeline

Jan 16, 2023 → Oct 30, 2023

NCT ID
NCT05633953

About Osilodrostat

Osilodrostat is a pre-clinical stage product being developed by Recordati for Cushing's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05633953. Target conditions include Cushing's Syndrome.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (4)

NCT IDPhaseStatus
NCT06430528Pre-clinicalRecruiting
NCT05633953Pre-clinicalCompleted
NCT05382156Pre-clinicalActive
NCT03606408Phase 2Completed

Competing Products

18 competing products in Cushing's Syndrome

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
52
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
77
Pasireotide sub-cutaneousNovartisPhase 3
77
osilodrostat + osilodrostat PlaceboNovartisPhase 3
77
OsilodrostatNovartisPhase 2
52
PasireotideNovartisPhase 3
77
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
85
SOM230 s.c.NovartisPhase 2
52
Lu AG13909LundbeckPhase 2
49
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
82
osilodrostatRecordatiPhase 2
49
OsilodrostatRecordatiPre-clinical
20
mifepristoneCorcept TherapeuticsPhase 3
72
CORT125134Corcept TherapeuticsPhase 2
47
Cushing's syndrome confirmationCorcept TherapeuticsPre-clinical
18
MifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72
mifepristoneCorcept TherapeuticsPhase 3
72

Other Products from Recordati

Intervention/TreatmentApproved
82
Osilodrostat (Isturisa)Approved
82
Pasireotide + Cabergoline + Pasireotide LARApproved
82
PlenvuApproved
82
SilodosinApproved
82